Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Will Indian pharma buckle under regulations?
Tue, 21 Apr Pre-Open

Indian pharma companies have been facing the heat from a stringent US Food and Drug Administration (USFDA). As a majority of domestic generic companies derive a lion's share of revenues from the US market, the largest number of FDA-approved plants outside the US belongs to them.

In recent times, several domestic pharma companies have been pulled up for data integrity issues that include deficiency in manufacturing practices and drug tests. This has led to import alerts against companies such Sun Pharma, Wockhardt, Cadila Pharma, Orchid Pharma and Ipca Labs. In extreme cases, companies such as Ranbaxy were penalized with import bans imposed on some of its plants.

Apart from this, higher vigilance by USFDA has led to increase in waiting period for new drug approvals from 30 months to 42 months. This has pulled down the number of approvals from 100 in FY14 to 57 in FY15. Resultantly, domestic drug companies are expected to witness pressure on earnings in the short run.

However, the long term demand potential for generic drug companies remains bright. Indian drug companies have been strengthening quality and control processes to comply with USFDA's strict rules. As a result, the number of import alerts has come down from 21 in 2013 to 8 in 2014 (Source: India Ratings and Research).

According to The World Generic Medicines Congress Europe 2015, the patent on drugs valued at US$ 170 bn are set to expire in 2015 spurring demand for generics with the US market alone accounting for a huge share of 86-87%. It remains to be seen how well Indian drug companies will gear up to tap this huge off-patent drugs opportunity.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Will Indian pharma buckle under regulations?". Click here!


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Jan 19, 2018 (Close)